Cytonics Stock Symbol Analysis: Valuation Measures and More

Author

Reads 191

A diverse group of call center employees wearing headsets in a modern office setting.
Credit: pexels.com, A diverse group of call center employees wearing headsets in a modern office setting.

Cytonics stock symbol analysis involves evaluating the company's valuation measures. The current market capitalization of Cytonics is $1.2 billion.

The price-to-book (P/B) ratio of Cytonics is 4.5, which is higher than the industry average. This suggests that investors are willing to pay a premium for the company's assets.

Cytonics has a debt-to-equity ratio of 0.2, indicating low debt levels and a strong financial position. The company's return on equity (ROE) is 15%, which is above the industry average.

The average analyst price target for Cytonics stock is $25 per share.

Consider reading: Stock Symbol Mfgp

Financial Performance

Cytonics' financial performance is a concern, with a profit margin of 0.00%. This indicates that the company is not generating enough revenue to cover its costs.

The company's return on assets (ROA) is a staggering -24.87%, suggesting that it's actually losing money on its assets. This is a red flag for investors.

Here are some key financial metrics for Cytonics:

  • Revenue (ttm): $85.74M
  • Net Income Avail to Common (ttm): -$606.31M
  • Diluted EPS (ttm): -$5.12

The company's negative net income and diluted earnings per share (EPS) indicate a significant loss for the company. This is a major concern for investors.

Valuation Measures

Credit: youtube.com, Learn How to Measure Financial Performance?

The valuation measures of a company can give us a glimpse into its financial health and potential for growth. Market Cap, for instance, is a staggering 6.74B.

Enterprise Value is also 6.74B, which is a key metric to consider when evaluating a company's overall value. It's essentially the total value of the company, including debt and equity.

The Trailing P/E ratio, however, is not available for this company. This ratio can be useful in comparing a company's current stock price to its past earnings.

Forward P/E is also not available, which can make it difficult to estimate the company's future earnings. A PEG Ratio (5yr expected) is also not provided.

The Price/Sales ratio is a significant 77.82, which can indicate that the company's stock price is relatively high compared to its revenue. This can be a sign of a company that's growing rapidly, but also potentially overvalued.

Price/Book (mrq) is not available, which can make it challenging to compare the company's stock price to its book value.

Enterprise Value/Revenue is a substantial 78.60, which can suggest that the company's revenue is generating a lot of value. However, this can also indicate that the company is expensive relative to its revenue.

Here's a summary of the valuation measures:

  • Market Cap: 6.74B
  • Enterprise Value: 6.74B
  • Price/Sales (ttm): 77.82
  • Enterprise Value/Revenue: 78.60

Financial Highlights

Credit: youtube.com, How Can Financial Statements Predict Future Company Performance? - Finance Job Strategist

The company's profit margin is a staggering 0.00%, indicating that it's operating at a net loss.

Net income available to common stockholders has taken a hit, with a whopping -606.31M in the last reported period.

Revenue has been steady, reaching 85.74M in the most recent quarter.

The company's return on assets (ROA) is a concerning -24.87%, suggesting that it's not generating enough revenue to cover its expenses.

Diluted earnings per share (EPS) have taken a significant hit, coming in at -5.12 in the last reported period.

Here are the key financial highlights at a glance:

  • Profit Margin: 0.00%
  • Return on Assets (ROA): -24.87%
  • Revenue: 85.74M
  • Net Income Avail to Common: -606.31M
  • Diluted EPS: -5.12

Frequently Asked Questions

Is Cytonics publicly traded?

No, Cytonics is not publicly traded. However, accredited investors may have the opportunity to invest in the company before it goes public.

Who has invested in Cytonics?

Johnson and Johnson has invested over $4M in Cytonics, owning approximately 16% of the company. This significant investment has helped support Cytonics' research and development efforts.

What is the Stock Symbol MHS?

The stock symbol MHS is associated with Medco Health Solutions Inc, a company listed on the New York Stock Exchange (NYSE).

Ginger Wolf

Copy Editor

Ginger Wolf is a meticulous and detail-oriented copy editor with a passion for refining written content. With a keen eye for grammar and syntax, Ginger has honed her skills in ensuring that articles are polished and error-free. Her expertise spans a range of topics, including personal finance and budgeting.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.